Listen in as Mike and Darren share how new modalities and manufacturing technologies have altered the partnership landscape between developers and CDMOs.

Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: Learn more on considerations for choosing the right CDMO for your late-stage biotherapeutics programs in this interview with Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics.

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 3 of 3 in the mRNA fireside chat series with Catalent’s experts).

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 2 of 3 in the mRNA fireside chat series with Catalent’s experts).

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 1 of 3 in the mRNA fireside chat series with Catalent’s experts).

Summary: In this executive summary, discover how Catalent’s Manufacturing by Design (MbD) strategy can help achieve efficiencies, drive cost savings, and develop and implement a robust, reproducible manufacturing plan for late-stage and commercial launch.

Summary: Watch this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimized...

Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...